Lucid Diagnostics shares jump 22.31% intraday after securing VA contract for EsoGuard test covering 9M veterans.

Lucid Diagnostics surged 22.31% intraday after the company announced winning a U.S. Department of Veterans Affairs contract to expand its EsoGuard esophageal DNA test to over 9 million veterans through the national VA healthcare system. The contract aligns with Medicare reimbursement rates. The company is a commercial-stage cancer prevention diagnostics firm focused on early detection of esophageal cancer, with the EsoGuard test targeting patients at risk for gastroesophageal reflux disease (GERD).